Replies to post #313 on Cascadian Therapeutics (CASC)

[io_io]

News - START - the trial continues per Merck KGaA ->

ONTY 8k filing : http://biz.yahoo.com/e/101222/onty8-k.html

22-Dec-2010

Item 8.01 Other Events.

On December 22, 2010, Merck Serono, a division of Merck KGaA of Darmstadt, Germany, informed Oncothyreon Inc. that the Independent Data Monitoring Committee (DMC) for the Phase 3 START trial of Stimuvax in non-small cell lung cancer (NSCLC) met and the DMC recommendation is to continue the study.